vs

Side-by-side financial comparison of Nakamoto Inc. (NAKA) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.

Scinai Immunotherapeutics Ltd. is the larger business by last-quarter revenue ($773.0K vs $444.9K, roughly 1.7× Nakamoto Inc.). On growth, Scinai Immunotherapeutics Ltd. posted the faster year-over-year revenue change (172.2% vs -26.3%).

NAKA vs SCNI — Head-to-Head

Bigger by revenue
SCNI
SCNI
1.7× larger
SCNI
$773.0K
$444.9K
NAKA
Growing faster (revenue YoY)
SCNI
SCNI
+198.5% gap
SCNI
172.2%
-26.3%
NAKA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
NAKA
NAKA
SCNI
SCNI
Revenue
$444.9K
$773.0K
Net Profit
$37.3M
Gross Margin
Operating Margin
-41198.2%
Net Margin
8374.2%
Revenue YoY
-26.3%
172.2%
Net Profit YoY
3820.2%
EPS (diluted)
$0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NAKA
NAKA
SCNI
SCNI
Q4 25
$444.9K
Q3 25
$388.2K
Q2 25
$408.5K
$773.0K
Q1 25
$579.7K
Q4 24
$603.9K
Q3 24
$647.9K
Q2 24
$639.1K
$284.0K
Q1 24
$829.0K
Net Profit
NAKA
NAKA
SCNI
SCNI
Q4 25
$37.3M
Q3 25
$-86.0M
Q2 25
$-2.4M
Q1 25
$-1.0M
Q4 24
$-1.0M
Q3 24
$-1.0M
Q2 24
$-1.3M
Q1 24
$-282.3K
Operating Margin
NAKA
NAKA
SCNI
SCNI
Q4 25
-41198.2%
Q3 25
-2680.4%
Q2 25
-585.4%
Q1 25
-179.7%
Q4 24
-169.3%
Q3 24
-162.0%
Q2 24
-162.3%
Q1 24
-28.6%
Net Margin
NAKA
NAKA
SCNI
SCNI
Q4 25
8374.2%
Q3 25
-22162.2%
Q2 25
-590.9%
Q1 25
-179.1%
Q4 24
-165.8%
Q3 24
-156.5%
Q2 24
-206.5%
Q1 24
-34.1%
EPS (diluted)
NAKA
NAKA
SCNI
SCNI
Q4 25
$0.68
Q3 25
$-0.42
Q2 25
$-0.35
Q1 25
$-0.17
Q4 24
$-0.18
Q3 24
$-0.17
Q2 24
$-0.26
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NAKA
NAKA
SCNI
SCNI
Cash + ST InvestmentsLiquidity on hand
$22.6M
$989.0K
Total DebtLower is stronger
Stockholders' EquityBook value
$514.3M
$7.9M
Total Assets
$730.6M
$11.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NAKA
NAKA
SCNI
SCNI
Q4 25
$22.6M
Q3 25
$24.2M
Q2 25
$6.0M
$989.0K
Q1 25
$1.1M
Q4 24
$2.3M
Q3 24
$3.6M
Q2 24
$4.7M
$3.1M
Q1 24
$287.4K
Total Debt
NAKA
NAKA
SCNI
SCNI
Q4 25
Q3 25
Q2 25
Q1 25
$64.4K
Q4 24
$148.8K
Q3 24
$205.6K
Q2 24
$254.7K
Q1 24
$710.0K
Stockholders' Equity
NAKA
NAKA
SCNI
SCNI
Q4 25
$514.3M
Q3 25
$477.6M
Q2 25
$9.0M
$7.9M
Q1 25
$1.5M
Q4 24
$2.6M
Q3 24
$3.5M
Q2 24
$4.4M
$-7.3M
Q1 24
$-383.1K
Total Assets
NAKA
NAKA
SCNI
SCNI
Q4 25
$730.6M
Q3 25
$692.4M
Q2 25
$9.9M
$11.8M
Q1 25
$2.6M
Q4 24
$3.7M
Q3 24
$4.3M
Q2 24
$5.5M
$14.9M
Q1 24
$799.3K
Debt / Equity
NAKA
NAKA
SCNI
SCNI
Q4 25
Q3 25
Q2 25
Q1 25
0.04×
Q4 24
0.06×
Q3 24
0.06×
Q2 24
0.06×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NAKA
NAKA
SCNI
SCNI
Operating Cash FlowLast quarter
$-23.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.63×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NAKA
NAKA
SCNI
SCNI
Q4 25
$-23.5M
Q3 25
$-13.2M
Q2 25
$-1.9M
Q1 25
$-865.1K
Q4 24
$-3.1M
Q3 24
$-1.0M
Q2 24
$-913.5K
Q1 24
$-213.4K
Free Cash Flow
NAKA
NAKA
SCNI
SCNI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-3.1M
Q3 24
$-1.0M
Q2 24
Q1 24
$-224.6K
FCF Margin
NAKA
NAKA
SCNI
SCNI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-511.2%
Q3 24
-161.7%
Q2 24
Q1 24
-27.1%
Capex Intensity
NAKA
NAKA
SCNI
SCNI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.2%
Q3 24
0.3%
Q2 24
0.0%
Q1 24
1.3%
Cash Conversion
NAKA
NAKA
SCNI
SCNI
Q4 25
-0.63×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons